From: Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights
Study Agents | Other agents | Disease | Dosage | Clinical trails | No Pts | Response | Reference |
---|---|---|---|---|---|---|---|
decitabine | GO | Elderly, untreated AML | 20 mg/m2 IV ×5d, GO 3 mg/m2 IV × 1 d 5 | Phase II | 33 | CR/CRp: 42% | [39] |
decitabine | GO | Relapsed and refractory AML | 20 mg/m2 IV ×5d | retrospective | 79 | CR/CRp: 21% | [40] |
Azacytidine | Â | Elderly relapsed and refractory AML | 75 mg/m2/d IV, d1-7 | retrospective | 184 | CR/CRi: 10% | [41] |
Azacytidine | gemtuzumab ozogamicin (GO) | high-risk AML | 75 mg/m2/d IV, d1-7 | retrospective | 56 | CR/CRi: 10% | [42] |
Azacytidine | Bortezomib | Relapsed and refractory AML | 75 mg/m2/d IV, d1-7 | Phase I | 23 | CR/CRi: 21% | [43] |